CARMUSTINE
Primary Systemic Amyloidosis
Roswell Park Cancer InstituteSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Primary Systemic Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Margarida Magalhaes-Silverman | Phase 2 | B |
EVUZAMITIDE University of Tennessee Graduate School of Medicine | Phase 1/2 | B |
Evomela Margarida Magalhaes-Silverman | Phase 2 | B |
ETOPOSIDE Margarida Magalhaes-Silverman | Phase 2 | B |
Bortezomib Margarida Magalhaes-Silverman | Phase 2 | B |
View all 24 →
Same molecule, other indications
CARMUSTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →